Novelion Therapeutics Inc Revenue Growth Rates (NVLN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Novelion Therapeutics Inc   (NVLN)
 

NVLN's Revenue Growth by Quarter and Year

Novelion Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVLN Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 32.20
FY 32.20





NVLN Revenue first quarter 2019 Y/Y Growth Comment
Novelion Therapeutics Inc achieved in the first quarter 2019, above Company average Revenue increase of 17.18% year on year, to $ 32.20 millions.

Looking into first quarter 2019 results within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Revenue growth. While Novelion Therapeutics Inc ' s Revenue growth of 17.18% ranks overall at the positon no. 1182 in the first quarter 2019.


NVLN Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December - 4.63 % 186.74 % -
3rd Quarter September - 5.79 % - -
2nd Quarter June - -21.97 % - -
1st Quarter March 17.18 % -8.34 % - -
FY   - -5.79 % 920.19 % -

Financial Statements
Novelion Therapeutics Inc 's first quarter 2019 Revenue $ 32.20 millions NVLN's Income Statement
Novelion Therapeutics Inc 's first quarter 2018 Revenue $ 27.48 millions Quarterly NVLN's Income Statement


NVLN Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - 34.22 % 35.72 % -
3rd Quarter September - -4.92 % -29.87 % -
2nd Quarter June - 16.08 % 36.36 % -
1st Quarter March -20.9 % -29.38 % 120.93 % -
FY (Year on Year)   - -5.79 % 920.19 % -


Back to NVLN Growth rate Comparisons >> Back to NVLN Growth rate Comparisons >>


Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #247
Overall #1182

Revenue Y/Y Growth Statistics
High Average Low
17.16 % -0.54 % -21.95 %
(Mar 31 2019)   (Jun 30 2018)
Revenue first quarter 2019 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #117
Healthcare Sector #247
Overall #1182
Revenue Y/Y Growth Statistics
High Average Low
17.16 % -0.54 % -21.95 %
(Mar 31 2019)   (Jun 30 2018)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Novelion Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
36.33 % 4.66 % -29.87 %
(Jun 30 2017)  


NVLN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2019 Novelion Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -20.9% to $ 32.20 millions, from $ 40.71 millions achived in the previous reporting period.

But that's not important problem, as Novelion Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 115 other companies have achieved higher Revenue quarter on quarter growth. While Novelion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3265.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #116
Healthcare Sector #393
Overall #3265
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #116
Healthcare Sector #393
Overall #3265
Revenue Q/Q Growth Statistics
High Average Low
36.33 % 4.66 % -29.87 %
(Jun 30 2017)  


NVLN's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2019 Novelion Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -20.9% to $ 32.20 millions, from $ 40.71 millions achived in the previous reporting period.

But that's not important problem, as Novelion Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 115 other companies have achieved higher Revenue quarter on quarter growth. While Novelion Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3265.


Novelion Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)		 12 Months Ending
(Jun 30 2018)		 12 Months Ending
(Mar 31 2018)
Cumulative Revenue 12 Months Ending $ 135.15 $ 130.43 $ 128.63 $ 126.97 $ 135.94
Y / Y Revenue Growth (TTM) -0.58 % -5.78 % 13.73 % - -
Year on Year Revenue Growth Overall Ranking # 3080 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 3.62 % 1.4 % 1.31 % -6.6 % -1.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 2859 # 1034 # 0 # 0 # 2858


Cumulative Revenue growth Comment
Novelion Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2018. If the fiscal year would end in Mar 31 2019, Novelion Therapeutics Inc 's annual Revenue decline would be -0.58% year on year to $135 millions.

In the Healthcare sector 383 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3080.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 384
Overall # 3080

Revenue TTM Y/Y Growth Statistics
High Average Low
-0.58 %
 -3.18 %
-5.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 355
S&P 500 # 2859
Cumulative Revenue growth Comment
Novelion Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Dec 31 2018. If the fiscal year would end in Mar 31 2019, Novelion Therapeutics Inc 's annual Revenue decline would be -0.58% year on year to $135 millions.

In the Healthcare sector 383 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3080.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 384
Overall # 3080

Revenue TTM Y/Y Growth Statistics
High Average Low
-0.58 %
-3.18 %
-5.78 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 138
Sector # 355
S&P 500 # 2859




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVLN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Mar 31 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2019
Viemed Healthcare Inc 29.74%$ 29.736 millions
Adm Tronics Unlimited Inc 29.13%$ 29.132 millions
Insulet Corporation29.11%$ 29.113 millions
Acadia Pharmaceuticals Inc 28.83%$ 28.835 millions
Societal Cdmo Inc 28.26%$ 28.262 millions
Dariohealth Corp 27.68%$ 27.677 millions
Addus Homecare Corp27.23%$ 27.233 millions
Biocept Inc 26.93%$ 26.928 millions
Sanara Medtech Inc 26.77%$ 26.767 millions
Align Technology inc 25.64%$ 25.645 millions
Guardion Health Sciences Inc 25.64%$ 25.641 millions
Neuronetics Inc 25.37%$ 25.374 millions
Horizon Therapeutics Public Limited Company25.23%$ 25.232 millions
Penumbra Inc25.06%$ 25.061 millions
Interpace Biosciences Inc 24.97%$ 24.974 millions
Pro dex Inc 24.75%$ 24.754 millions
Aspira Women s Health inc 23.73%$ 23.729 millions
Koru Medical Systems Inc 23.33%$ 23.333 millions
Medpace Holdings Inc 23.10%$ 23.096 millions
Syros Pharmaceuticals Inc 22.70%$ 22.703 millions
Alexion Pharmaceuticals Inc 22.51%$ 22.505 millions
Pacira Biosciences inc 22.39%$ 22.392 millions
Charles River Laboratories International inc 22.39%$ 22.390 millions
Perspective Therapeutics Inc 22.31%$ 22.314 millions
Luna Innovations Inc21.65%$ 21.651 millions
Fonar Corporation21.64%$ 21.641 millions
Orthopediatrics Corp21.18%$ 21.184 millions
Vericel Corporation20.99%$ 20.985 millions
Avalo Therapeutics Inc 20.72%$ 20.716 millions
Capforce Inc 20.56%$ 20.556 millions


About Novelion Therapeutics Inc Revenue Growth Rates (NVLN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.